Last reviewed · How we verify
Corgard (NADOLOL)
Corgard (nadolol) is a beta-adrenergic blocker, a small molecule drug developed by King Pharmaceuticals and currently owned by Uswm. It targets the beta-2 adrenergic receptor to treat angina pectoris and hypertensive disorders. Corgard was FDA-approved in 1979 and is now off-patent with 13 generic manufacturers. The drug has a half-life of 9.2 hours and bioavailability of 30%. It is used to reduce heart rate and blood pressure in patients with these conditions.
At a glance
| Generic name | NADOLOL |
|---|---|
| Sponsor | Uswm |
| Drug class | beta-Adrenergic Blocker [EPC] |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1979 |
Approved indications
- Angina pectoris
- Hypertensive disorder
Boxed warnings
- Exacerbation of Ischemic Heart Disease Following Abrupt Withdrawal Hypersensitivity to catecholamines has been observed in patients withdrawn from beta-blocker therapy; exacerbation of angina and, in some cases, myocardial infarction have occurred after abrupt discontinuation of such therapy. When discontinuing chronically administered nadolol, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of one to two weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, nadolol administration should be reinstituted promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician's advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue nadolol therapy abruptly even in patients treated only for hypertension.
Common side effects
- bradycardia with heart rates below 40 beats per minute and/or symptomatic bradycardia
- peripheral vascular insufficiency, usually of the Raynaud type
- cardiac failure
- hypotension
- rhythm/conduction disturbances
- dizziness or fatigue
- paresthesias
- sedation
- change in behavior
- bronchospasm
Drug interactions
- piroxicam
- sulindac
- tolazamide
- tolbutamide
- verapamil
Key clinical trials
- MEdical Treatment in Idiopathic Ventricular Fibrillation Patients (PHASE4)
- N-of-1 for Beta-Blockers in Cardiac Amyloidosis (PHASE4)
- A Preliminary Study for INFORMED (PHASE4)
- Pre-emptive RTO for An Early Detected Gastric Varices in CT/MR Angiogram Trial (NA)
- A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders (PHASE2)
- Exercise as an Immune Adjuvant for Allogeneic Cell Therapies (EARLY_PHASE1)
- Fed Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg (PHASE1)
- Fasting Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Corgard CI brief — competitive landscape report
- Corgard updates RSS · CI watch RSS
- Uswm portfolio CI